The report provides insights into GSK's tech activities, including its digital transformation strategies, its innovation programs, and its technology ...

The pharmaceutical giant's revenue jumped 21 per cent last year despite growing troubles over its presence in China, where it ...

Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...